Search results
Results from the WOW.Com Content Network
Paradoxical effects, such as increased activity, can occur especially in children and older people. [16] There is evidence of risk when used during pregnancy but no evidence of harm with a single dose during breastfeeding. [17] [18] Midazolam was patented in 1974 and came into medical use in 1982. [19]
Phenylephrine – This drug is administered to those with hypotension post intubation as a result of lidocaine, midazolam, fentanyl, Propofol, and ketamine. The dosages range from 50 to 200 μg in adults. It has quick onset and quick elimination. The common side effect is reflex bradycardia. [8]
Midazolam collects in the body's fatty tissues, so a possible complication includes prolonged sedation. As a result, the elderly, the obese, and those with kidney or liver disease are more vulnerable to prolonged sedation with midazolam. Respiratory depression is also associated with midazolam when given in high doses.
Typical Oral Dosage Formulations (mg) Approx. Equivalent Oral Dose to 10 mg Diazepam [b] (mg) Peak Onset of Action (hours) Elimination Half-life of Active Metabolite (hours) Primary Therapeutic Use Adinazolam: Deracyn: Research chemical: 1–2: 3: anxiolytic, antidepressant: Alprazolam
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
The most commonly utilized benzodiazepine is Midazolam, which is characterized by a rapid onset and short duration. Midazolam is effective in reducing preoperative anxiety, including separation anxiety in children. [28] It also provides mild sedation, sympathicolysis, and anterograde amnesia. [6]
They most commonly occur in children between the ages of 6 months and 5 years. [1] [3] Most seizures are less than five minutes in duration, and the child is completely back to normal within an hour of the event. [1] [4] There are two types: simple febrile seizures and complex febrile seizures. [1]
Remimazolam was approved for medical use in the United States in July 2020. [5] [6]The U.S. Food and Drug Administration (FDA) approved remimazolam based on evidence from three clinical trials (Trial 1/NCT02290873, Trial 2/NCT02296892 and Trial 3/NCT02532647) in adults undergoing short procedures. [5]